398 related articles for article (PubMed ID: 24930824)
1. Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.
Fan P; Craig Jordan V
Steroids; 2014 Nov; 90():44-52. PubMed ID: 24930824
[TBL] [Abstract][Full Text] [Related]
2. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
[TBL] [Abstract][Full Text] [Related]
3. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Peng J; Sengupta S; Jordan VC
Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
Sengupta S; Jordan VC
Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
[TBL] [Abstract][Full Text] [Related]
5. SERMs (selective estrogen receptor modulator), acting as estrogen receptor β agonists in hepatocellular carcinoma cells, inhibit the transforming growth factor-α-induced migration via specific inhibition of AKT signaling pathway.
Matsushima-Nishiwaki R; Yamada N; Hattori Y; Hosokawa Y; Tachi J; Hori T; Kozawa O
PLoS One; 2022; 17(1):e0262485. PubMed ID: 35007301
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance.
Bergamaschi A; Katzenellenbogen BS
Oncogene; 2012 Jan; 31(1):39-47. PubMed ID: 21666713
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Park WC; Jordan VC
Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091
[TBL] [Abstract][Full Text] [Related]
9. New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis.
Jordan VC; Lewis-Wambi JS; Patel RR; Kim H; Ariazi EA
Breast; 2009 Oct; 18 Suppl 3(Suppl 3):S10-7. PubMed ID: 19914527
[TBL] [Abstract][Full Text] [Related]
10. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
[TBL] [Abstract][Full Text] [Related]
11. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation.
Nalbandian G; Paharkova-Vatchkova V; Mao A; Nale S; Kovats S
J Immunol; 2005 Aug; 175(4):2666-75. PubMed ID: 16081843
[TBL] [Abstract][Full Text] [Related]
12. Water extract of Er-xian decoction selectively exerts estrogenic activities and interacts with SERMs in estrogen-sensitive tissues.
Wong KY; Zhou L; Yu W; Poon CC; Xiao H; Chan CO; Mok DK; Wong MS
J Ethnopharmacol; 2021 Jul; 275():114096. PubMed ID: 33823166
[TBL] [Abstract][Full Text] [Related]
13. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).
Lewis-Wambi JS; Jordan VC
Breast Dis; 2005-2006; 24():93-105. PubMed ID: 16917142
[TBL] [Abstract][Full Text] [Related]
15. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
16. Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
Price S; Bender SG; Yahn R; Till NA; Varady S; LaLonde RL
Bioorg Med Chem Lett; 2021 Nov; 52():128383. PubMed ID: 34592434
[TBL] [Abstract][Full Text] [Related]
17. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.
Fan P; Agboke FA; Cunliffe HE; Ramos P; Jordan VC
Eur J Cancer; 2014 Nov; 50(16):2866-76. PubMed ID: 25204804
[TBL] [Abstract][Full Text] [Related]
18. Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.
Ariazi EA; Lewis-Wambi JS; Gill SD; Pyle JR; Ariazi JL; Kim HR; Sharma CG; Cordera F; Shupp HA; Li T; Jordan VC
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):128-38. PubMed ID: 17085047
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.
Balaburski GM; Dardes RC; Johnson M; Haddad B; Zhu F; Ross EA; Sengupta S; Klein-Szanto A; Liu H; Lee ES; Kim H; Jordan VC
Int J Oncol; 2010 Aug; 37(2):387-98. PubMed ID: 20596666
[TBL] [Abstract][Full Text] [Related]
20. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
